ResultsIQ

ResultsIQ › Latest results › Symphony Limited

Symphony Limited Q4 FY26 earnings call summary

NSE: SYMPHONY · BSE: 517385

Earnings call of 18 May 2026, summarised by AI from the filing.

GSK China to repay ₹4 cr loan in next 6 months; entire price increase to be passed from 1st July.

Key takeaways

  1. Guidance GSK China to repay ₹4 cr loan in next 6 months; entire price increase to be passed from 1st July.
  2. Australia reset Entire ₹348 cr equity investment impaired; no further capital allocation to Australia business.
  3. BISP driver BISP portfolio ₹558 cr, 49% of FY26 consolidated revenue, derisking through product and geographic diversification.
  4. Risk Channel inventory overhang and bad summer of '25 caused caution; weather remains uncertain.

Original filing on BSE

Symphony Limited Q1 FY27 results

As filed: Revenue ₹378 cr (+51% year on year), EBITDA ₹46.0 cr (+77% year on year), PAT ₹40.0 cr (−5% year on year), EBITDA margin 12.2% (+181 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹338 cr, EBITDA ₹50.0 cr, PAT −₹218 cr, EBITDA margin 14.8%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹338 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: −14.6% in 28 days (Nifty 500: +0.3%).
  • Q3 FY26: Revenue ₹179 cr (−26% year on year), EBITDA ₹29.0 cr (0% year on year), PAT ₹20.0 cr, EBITDA margin 16.2% (+422 bps). Score 42 of 100, In line with trend. Revenue and EBITDA growth were below the company's own trend. EBITDA margin rose 422 bps year on year. Share price after the results: −3.3% in 30 days (Nifty 500: +0.4%).
  • Q2 FY26: Revenue ₹163 cr (−48% year on year), EBITDA ₹24.0 cr (−63% year on year), PAT ₹19.0 cr (−66% year on year), EBITDA margin 14.7% (−559 bps). Score 19 of 100, Below trend. Revenue growth was well below the company's own trend; EBITDA and profit growth were below it. EBITDA margin fell 559 bps year on year. Other income 38% of PBT. Revenue fell 35% from last quarter. Share price after the results: −6.8% in 29 days (Nifty 500: +0.7%).
  • Q1 FY26: Revenue ₹251 cr (−53% year on year), EBITDA ₹26.0 cr (−77% year on year), PAT ₹42.0 cr (−52% year on year), EBITDA margin 10.4% (−1,000 bps). Score 11 of 100, Below trend. Revenue and EBITDA growth were well below the company's own trend; profit growth was below it. EBITDA margin fell 1000 bps year on year. Other income 42% of PBT. Share price after the results: −16.3% in 28 days (Nifty 500: −2.0%).
  • H2 FY25: Revenue ₹488 cr, EBITDA ₹107 cr, PAT ₹79.0 cr, EBITDA margin 21.9%. Not scored. No consolidated results for the same half-year last year to compare yet (consolidated revenue ₹488 cr). Scored once a year-earlier consolidated half-year exists. Share price after the results: −4.1% in 30 days (Nifty 500: +5.0%).
  • Q3 FY25: Revenue ₹242 cr (−2% year on year), EBITDA ₹29.0 cr (−34% year on year), PAT −₹10.0 cr (−44% year on year), EBITDA margin 12.0% (−583 bps). Score 23 of 100, Below trend. Revenue growth was below the company's own trend; EBITDA and profit before exceptional items growth were well below it. EBITDA margin fell 583 bps year on year. Revenue fell 23% from last quarter.
  • Q2 FY25: Revenue ₹315 cr (+15% year on year), EBITDA ₹64.0 cr (+56% year on year), PAT ₹56.0 cr (+60% year on year), EBITDA margin 20.3% (+541 bps). Score 77 of 100, Above trend. EBITDA margin rose 541 bps year on year. Other income 26% of PBT. Not enough history for a trend yet: scored on growth alone. Revenue fell 41% from last quarter.

Past price moves after results do not indicate future moves. Not a recommendation.

Symphony Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.